Related Experiment Videos
IVGG therapy in Kawasaki disease: mechanism(s) of action
1Children's Memorial Hospital, Northwestern University Medical School, Chicago, Illinois 60614.
Insights
Kawasaki disease, a pediatric illness causing heart issues, is treated with IVGG. Early IVGG administration significantly reduces inflammation and coronary abnormalities in children.
Area of Science:
- Pediatric Cardiology
- Immunology
- Infectious Diseases
Background:
- Kawasaki disease is a leading cause of acquired heart disease in children in developed nations.
- Coronary artery abnormalities affect 20-25% of patients, potentially leading to myocardial ischemia.
- The exact cause of Kawasaki disease remains unknown, though an infectious origin is suspected.
Purpose of the Study:
- To summarize the effects of Intravenous Immunoglobulin (IVGG) in treating Kawasaki disease.
- To explore potential mechanisms by which IVGG exerts its therapeutic effects.
- To highlight the reduction in coronary abnormalities following early IVGG intervention.
Main Methods:
- Review of controlled studies investigating IVGG treatment for Kawasaki disease.
- Assessment of coronary abnormalities using echocardiography and angiography.
- Analysis of proposed mechanisms of IVGG action.
Main Results:
- Early IVGG administration shows a significant anti-inflammatory effect.
- IVGG treatment markedly reduces the development of coronary abnormalities.
- Studies indicate IVGG is effective in managing Kawasaki disease complications.
Conclusions:
- IVGG is a crucial treatment for Kawasaki disease, reducing cardiac complications.
- Understanding IVGG's mechanism could offer insights into Kawasaki disease pathogenesis.
- Further research is needed to clarify the precise action of IVGG.
Abstract:
Kawasaki disease (mucocutaneous lymph node syndrome) has emerged as a major pediatric disorder throughout the developed world, including the United States where it is now a leading cause of acquired heart disease in children. Coronary artery abnormalities, including ectasia, aneurysms, stenosis, and thrombosis, that may result in myocardial ischemia and/or infarction, develop in approximately 20-25% of patients as a consequence of coronary arteritis. Although epidemiologic and clinical findings strongly suggest an infectious etiology, the etiology of Kawasaki disease remains unknown. Marked immune activation is present in the acute state of Kawasaki disease. Investigators in Japan and a U.S. multicenter investigative group have demonstrated in controlled studies that administration of IVGG early in the course of Kawasaki disease is associated with (i) a striking anti-inflammatory effect, and (ii) a marked reduction in the development of coronary abnormalities, as assessed by echocardiography and/or angiography. The mechanism(s) by which IVGG produces these dramatic effects is unclear. Possible mechanisms include (i) Fc receptor blockade, (ii) a direct anti-etiologic agent (neutralization) effect, (iii) an anti-toxic effect, (iv) an immunomodulating effect possibly mediated either by anti-idiotypic antibodies or by induction of suppressor T cells, and (v) down-regulation of cytokine production by activated immune cells. Clarification of the mechanism of action of IVGG in Kawasaki disease should provide insights into the pathogenesis and/or the etiology of this fascinating disorder.